Ysios Capital anuncia la salida a bolsa en el NASDAQ de su participada Galecto, Inc

Desinversión, Venture Capital

12/11/2020 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PARTICIPADA GALECTO, INC. Ysios Capital, gestora española de capital riesgo (venture capital) líder en inversiones en el sector biotecnológico, ha anunciado hoy la salida a bolsa en el NASDAQ de su compañía participada Galecto, Inc. (NASDAQ: GLTO) a…

Ysios Capital participates in its portfolio company Galecto $64 Million financing to accelerate development of clinical pipeline

Inversión, Venture Capital

28/09/2020 Press release GALECTO RAISES $64 MILLION TO ACCELERATE DEVELOPMENT OF CLINICAL PIPELINE.   Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful…